Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Siglec-1 on dendritic cells mediates SARS-CoV-2 trans-infection of target cells while on macrophages triggers proinflammatory responses

  • Perez-Zsolt, Daniel
  • Muñoz-Basagoiti, Jordana
  • Rodón, Jordi
  • Elousa, Marc
  • Raïch-Regué, Dàlia
  • Risco, Cristina
  • Sachse, Martín
  • Pino, María
  • Gumber, Sanjeev
  • Paiardini, Mirko
  • Chojnacki, Jakub
  • Erkizia, tziar
  • Muñiz-Trabudua, Xabier
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Noguera, Marc
  • Paredes, Roger
  • Trinité, Benjamin
  • Tarrés-Freixas, Ferrán
  • Blanco, Ignacio
  • Guallar, Victor
  • Carrillo, Jorge
  • Blanco, Julià
  • Telenti, Amalio
  • Heyn, Holger
  • Segalés, Joaquim
  • Clotet, Bonaventura
  • Martínez-Picado, Javier
  • Vergara-Alert, Júlia
  • Izquierdo-Useros, Núria
COVID-19 pandemic is not yet under control by vaccination, and effective antivirals are critical for preparedness. Here we report that macrophages and dendritic cells, key antigen presenting myeloid cells (APCs), are largely resistant to SARS-CoV-2 infection. APCs effectively captured viruses within cellular compartments that lead to antigen degradation. Macrophages sense SARS-CoV-2 and released higher levels of cytokines, including those related to cytokine storm in severe COVID-19. The sialic acid-binding Ig-like lectin 1 (Siglec-1/CD169) present on APCs, which interacts with sialylated gangliosides on membranes of retroviruses or filoviruses, also binds SARS-CoV-2 via GM1. Blockage of Siglec-1 receptors by monoclonal antibodies reduces SARS-CoV-2 uptake and transfer to susceptible target cells. APCs expressing Siglec-1 and carrying SARS-CoV-2 are found in pulmonary tissues of non-human primates. Single cell analysis reveals the in vivo induction of cytokines in those macrophages. Targeting Siglec-1 could offer cross-protection against SARS-CoV-2 and other enveloped viruses that exploit APCs for viral dissemination, including those yet to come in future outbreaks., The research of CBIG consortium (constituted by IRTA-CReSA, BSC, & IrsiCaixa) is supported by Grifols pharmaceutical. The authors also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com). J.M-P. is supported by grant PID2019-109870RB-I00 from the Spanish Ministry of Science and Innovation and in part also by Grifols. CR lab is funded by RTI2018-094445-B100 (MCIU/AEI/FEDER, UE). The authors also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com). The NHP study was primarily supported by YNPRC Coronavirus Pilot Research Project Program grant to M.Pa. under award P51 OD11132, Emergent Venture Fast grant program to MPa under awards #2206 and #2144, and William and Lula Pitts Foundation (to MPa)., No
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

β-Cyclodextrins as affordable antivirals to treat coronavirus infection

  • Raïch-Regué, Dàlia|||0000-0001-7656-5700
  • Tenorio, Raquel
  • Fernández de Castro, Isabel
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Sachse, Martin
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Fernández-Sánchez, Sara Y.
  • Gallemí, Marçal|||0000-0003-4675-6893
  • Ortega-González, Paula
  • Fernández-Oliva, Alberto
  • Gabaldón, José A.
  • Nuñez-Delicado, Estrella
  • Casas, Josefina|||0000-0002-7926-5209
  • Roca, Núria
  • Cantero, Guillermo|||0000-0003-4200-503X
  • Pérez, Mónica
  • Usai, Carla|||0000-0002-6373-2765
  • Lorca-Oró, Cristina|||0000-0001-5351-4169
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Blanco, Julià|||0000-0002-2225-0217
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Cerón-Carrasco, José P.
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Risco, Cristina|||0000-0001-7501-5934
The SARS-CoV-2 pandemic made evident that there are only a few drugs against coronavirus. Here we aimed to identify a cost-effective antiviral with broad spectrum activity and high safety profile. Starting from a list of 116 drug candidates, we used molecular modelling tools to rank the 44 most promising inhibitors. Next, we tested their efficacy as antivirals against α and β coronaviruses, such as the HCoV-229E and SARS-CoV-2 variants. Four drugs, OSW-1, U18666A, hydroxypropyl-β-cyclodextrin (HβCD) and phytol, showed in vitro antiviral activity against HCoV-229E and SARS-CoV-2. The mechanism of action of these compounds was studied by transmission electron microscopy and by fusion assays measuring SARS-CoV-2 pseudoviral entry into target cells. Entry was inhibited by HβCD and U18666A, yet only HβCD inhibited SARS-CoV-2 replication in the pulmonary Calu-3 cells. Compared to the other cyclodextrins, β-cyclodextrins were the most potent inhibitors, which interfered with viral fusion via cholesterol depletion. β-cyclodextrins also prevented infection in a human nasal epithelium model ex vivo and had a prophylactic effect in the nasal epithelium of hamsters in vivo. All accumulated data point to β-cyclodextrins as promising broad-spectrum antivirals against different SARS-CoV-2 variants and distant alphacoronaviruses. Given the wide use of β-cyclodextrins for drug encapsulation and their high safety profile in humans, our results support their clinical testing as prophylactic antivirals.